AR027763A1 - Tratamiento de trastornos renales - Google Patents

Tratamiento de trastornos renales

Info

Publication number
AR027763A1
AR027763A1 ARP010101580A ARP010101580A AR027763A1 AR 027763 A1 AR027763 A1 AR 027763A1 AR P010101580 A ARP010101580 A AR P010101580A AR P010101580 A ARP010101580 A AR P010101580A AR 027763 A1 AR027763 A1 AR 027763A1
Authority
AR
Argentina
Prior art keywords
treatment
renal disorders
amlodipine
cats
renal
Prior art date
Application number
ARP010101580A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR027763A1 publication Critical patent/AR027763A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripta en este documento se refiere al uso de bloqueantes de los canales de calcio tales como amlodipino, en el tratamiento de la enfermedadrenal en animales normotensos. También se describen nuevas dosis unitarias de amlodipino adecua das para el tratamiento de la enfermedad renal en gatos.normotensos.
ARP010101580A 2000-04-04 2001-04-03 Tratamiento de trastornos renales AR027763A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (1)

Publication Number Publication Date
AR027763A1 true AR027763A1 (es) 2003-04-09

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101580A AR027763A1 (es) 2000-04-04 2001-04-03 Tratamiento de trastornos renales

Country Status (12)

Country Link
EP (1) EP1284719A2 (es)
JP (1) JP2003528927A (es)
AR (1) AR027763A1 (es)
AU (1) AU2001239510A1 (es)
BR (1) BR0109783A (es)
CA (1) CA2403950A1 (es)
GB (1) GB0008332D0 (es)
MX (1) MXPA02009819A (es)
PA (1) PA8514601A1 (es)
PE (1) PE20011163A1 (es)
TN (1) TNSN01051A1 (es)
WO (1) WO2001074390A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
WO2002053535A2 (en) * 2000-12-29 2002-07-11 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
DE20220415U1 (de) * 2001-11-07 2003-10-09 Synthon Bv Tamsulosin-Tabletten
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
AU2003264954A1 (en) 2002-09-30 2004-04-19 Kowa Company, Ltd. Pharmaceutical composition for prevention and treatment of kidney diseases
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
AU2006224161A1 (en) 2005-03-15 2006-09-21 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
JP2008539274A (ja) * 2005-04-29 2008-11-13 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコの寿命を延長する方法
EP3434284A4 (en) * 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
EP0459666B1 (en) * 1990-05-31 1994-11-09 Pfizer Inc. Medicaments against impotence
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
JPH07501547A (ja) * 1991-11-26 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
JPH11500140A (ja) * 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
AU2001239510A1 (en) 2001-10-15
WO2001074390A2 (en) 2001-10-11
CA2403950A1 (en) 2001-10-11
BR0109783A (pt) 2003-01-21
PE20011163A1 (es) 2001-11-12
EP1284719A2 (en) 2003-02-26
JP2003528927A (ja) 2003-09-30
MXPA02009819A (es) 2003-03-27
TNSN01051A1 (fr) 2005-11-10
PA8514601A1 (es) 2002-08-26
WO2001074390A3 (en) 2002-05-30
GB0008332D0 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
UY27098A1 (es) Derivados de indol
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
AR027763A1 (es) Tratamiento de trastornos renales
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
BRPI9907866B8 (pt) composição farmacêutica, bem como seu uso
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
BR0015254B1 (pt) compostos derivados de carbamoiloxialquil-azàlio, seu uso, bem como composiÇço farmacÊutica compreendendo os mesmos.
SV2008002906A (es) Metodos y composiciones para modular la hemostasiaref. cho.0267b-sv
AR056080A1 (es) 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
SV2004001549A (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
DE60035639D1 (de) Hydroxydiphenyletherverbindungen
PA8532201A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
BR0010702A (pt) Novas quinonas como terapias de doenças
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
BR0209430B1 (pt) compostos heterocíclicos, processo para sua preparação, composições para o combate de pragas animais, uso dos referidos compostos, bem como preparação das referidas composições
UY26265A1 (es) Compuestos calciolíticos
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
PA8571401A1 (es) Imidazolinilmetil aralquilsulfonamidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal